BR112018008966A2 - compostos inibidores de jak quinase para o tratamento de doença respiratória - Google Patents
compostos inibidores de jak quinase para o tratamento de doença respiratóriaInfo
- Publication number
- BR112018008966A2 BR112018008966A2 BR112018008966-4A BR112018008966A BR112018008966A2 BR 112018008966 A2 BR112018008966 A2 BR 112018008966A2 BR 112018008966 A BR112018008966 A BR 112018008966A BR 112018008966 A2 BR112018008966 A2 BR 112018008966A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- jak kinase
- compounds
- kinase inhibitor
- respiratory disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
a invenção fornece compostos de fórmula (i): em que x é (i) e as variáveis são definidas no relatório descritivo, ou um sal farmaceuticamente aceitável destes, que são úteis como inibidores de jak quinase. a invenção também fornece composições farmacêuticas que compreendem esses compostos, métodos de uso desses compostos para tratar doenças respiratórias, e processos e intermediários úteis para a preparação desses compostos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562250113P | 2015-11-03 | 2015-11-03 | |
US62/250,113 | 2015-11-03 | ||
PCT/US2016/059999 WO2017079205A1 (en) | 2015-11-03 | 2016-11-02 | Jak kinase inhibitor compounds for treatment of respiratory disease |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018008966A2 true BR112018008966A2 (pt) | 2018-11-27 |
BR112018008966B1 BR112018008966B1 (pt) | 2023-05-02 |
Family
ID=57442794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018008966-4A BR112018008966B1 (pt) | 2015-11-03 | 2016-11-02 | Compostos inibidores de jak quinase, hidrato cristalino, composição farmacêutica, processos, método de preparação do hidrato cristalino e uso dos referidos compostos e hidrato cristalino no tratamento de doença respiratória |
Country Status (21)
Country | Link |
---|---|
US (6) | US10100049B2 (pt) |
EP (1) | EP3371186A1 (pt) |
JP (1) | JP6800969B2 (pt) |
KR (1) | KR20180073687A (pt) |
CN (1) | CN108349972B (pt) |
AU (1) | AU2016350816B2 (pt) |
BR (1) | BR112018008966B1 (pt) |
CA (1) | CA3001542C (pt) |
CL (1) | CL2018001145A1 (pt) |
CO (1) | CO2018005640A2 (pt) |
EA (1) | EA034914B1 (pt) |
HK (1) | HK1252685A1 (pt) |
IL (1) | IL258772B (pt) |
MX (1) | MX2018005446A (pt) |
MY (1) | MY195427A (pt) |
NZ (1) | NZ741737A (pt) |
PH (1) | PH12018500828A1 (pt) |
SA (1) | SA518391470B1 (pt) |
TW (1) | TWI710560B (pt) |
UA (1) | UA123633C2 (pt) |
WO (1) | WO2017079205A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017077288A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
PT3712152T (pt) | 2015-11-03 | 2021-04-15 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase |
CN108349972B (zh) | 2015-11-03 | 2021-06-08 | 施万生物制药研发Ip有限责任公司 | 用于治疗呼吸疾病的jak激酶抑制剂化合物 |
AR111242A1 (es) | 2017-03-09 | 2019-06-19 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak |
RU2764979C2 (ru) * | 2017-05-01 | 2022-01-24 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Способы лечения с использованием соединения-ингибитора jak |
CA3059790A1 (en) * | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Crystalline forms of a jak inhibitor compound |
AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
US20200281857A1 (en) | 2017-11-22 | 2020-09-10 | Dauntless 1, Inc. | Therapeutic compound formulations |
EP3810094A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
KR20210056380A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 5원 내지 7원 헤테로사이클릭 아마이드 |
BR112021004087A2 (pt) * | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | processo para preparar inibidores de jak e seus intermediários |
KR20210056381A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 |
MX2021004582A (es) * | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
BR112021016751B8 (pt) * | 2019-02-25 | 2023-11-21 | Henan Medinno Pharmaceutical Tech Co Ltd | Compostos, composições farmacêuticas e usos dos compostos |
CA3132371A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN113121509B (zh) * | 2019-12-30 | 2024-04-26 | 河南迈英诺医药科技有限公司 | Jak抑制剂化合物及其用途 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
WO2022178215A1 (en) | 2021-02-19 | 2022-08-25 | Theravance Biopharma R&D Ip, Llc | Amino amide tetrahydro imidazo pyridines as jak inhibitors |
CA3212635A1 (en) * | 2021-03-26 | 2022-09-29 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a dihydrochloride salt of a jak inhibitor compound |
US20240092758A1 (en) * | 2021-06-25 | 2024-03-21 | Theravance Biopharma R&D Ip, Llc | Imidazolo indazole compounds as jak inhibitors |
CN114181055A (zh) * | 2021-12-21 | 2022-03-15 | 苏州楚凯药业有限公司 | 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法 |
WO2023215478A1 (en) | 2022-05-05 | 2023-11-09 | Theravance Biopharma R&D Ip, Llc | Nezulcitinib for delivery by nebulized oral inhalation |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
WO2005009389A2 (en) | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
CA2673125C (en) | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
CN102131389A (zh) | 2008-06-20 | 2011-07-20 | 健泰科生物技术公司 | ***并吡啶jak抑制剂化合物和方法 |
WO2010039825A2 (en) | 2008-10-01 | 2010-04-08 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ttk阻害作用を有するインダゾール誘導体 |
US20120029190A1 (en) | 2009-04-03 | 2012-02-02 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
CN102470135A (zh) | 2009-07-28 | 2012-05-23 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
JP5822844B2 (ja) | 2009-12-21 | 2015-11-24 | サミュメッド リミテッド ライアビリティ カンパニー | 1H−ピラゾロ[3,4−b]ピリジンおよびその治療的使用 |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
EP2643314B1 (en) | 2010-11-25 | 2016-07-13 | ratiopharm GmbH | Novel salts and polymorphic forms of afatinib |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
TW201513861A (zh) * | 2013-01-17 | 2015-04-16 | Galapagos Nv | 用於治療退化性及發炎疾病之新穎化合物 |
MX368464B (es) | 2013-12-05 | 2019-10-02 | Pfizer | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo. |
GEP20186921B (en) | 2014-05-14 | 2018-11-12 | Pfizer | Pyrazolopyridines and pyrazolopyrimidines |
WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
WO2017077288A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
PT3712152T (pt) | 2015-11-03 | 2021-04-15 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase |
CN108349972B (zh) | 2015-11-03 | 2021-06-08 | 施万生物制药研发Ip有限责任公司 | 用于治疗呼吸疾病的jak激酶抑制剂化合物 |
AR111242A1 (es) | 2017-03-09 | 2019-06-19 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak |
CA3059790A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Crystalline forms of a jak inhibitor compound |
RU2764979C2 (ru) | 2017-05-01 | 2022-01-24 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Способы лечения с использованием соединения-ингибитора jak |
AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
KR20210056381A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 |
KR20210056380A (ko) | 2018-09-04 | 2021-05-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제로서 5원 내지 7원 헤테로사이클릭 아마이드 |
BR112021004087A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | processo para preparar inibidores de jak e seus intermediários |
MX2021004582A (es) | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
CA3212635A1 (en) | 2021-03-26 | 2022-09-29 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a dihydrochloride salt of a jak inhibitor compound |
-
2016
- 2016-11-02 CN CN201680063886.1A patent/CN108349972B/zh active Active
- 2016-11-02 TW TW105135436A patent/TWI710560B/zh active
- 2016-11-02 EA EA201891091A patent/EA034914B1/ru unknown
- 2016-11-02 BR BR112018008966-4A patent/BR112018008966B1/pt active IP Right Grant
- 2016-11-02 EP EP16804947.6A patent/EP3371186A1/en not_active Withdrawn
- 2016-11-02 KR KR1020187015680A patent/KR20180073687A/ko not_active Application Discontinuation
- 2016-11-02 UA UAA201806062A patent/UA123633C2/uk unknown
- 2016-11-02 CA CA3001542A patent/CA3001542C/en active Active
- 2016-11-02 AU AU2016350816A patent/AU2016350816B2/en active Active
- 2016-11-02 NZ NZ741737A patent/NZ741737A/en unknown
- 2016-11-02 MY MYPI2018701385A patent/MY195427A/en unknown
- 2016-11-02 US US15/341,226 patent/US10100049B2/en active Active
- 2016-11-02 MX MX2018005446A patent/MX2018005446A/es active IP Right Grant
- 2016-11-02 JP JP2018522556A patent/JP6800969B2/ja active Active
- 2016-11-02 WO PCT/US2016/059999 patent/WO2017079205A1/en active Application Filing
-
2018
- 2018-04-17 IL IL258772A patent/IL258772B/en active IP Right Grant
- 2018-04-17 PH PH12018500828A patent/PH12018500828A1/en unknown
- 2018-04-30 CL CL2018001145A patent/CL2018001145A1/es unknown
- 2018-04-30 SA SA518391470A patent/SA518391470B1/ar unknown
- 2018-05-29 CO CONC2018/0005640A patent/CO2018005640A2/es unknown
- 2018-07-18 US US16/038,424 patent/US10183942B2/en active Active
- 2018-09-18 HK HK18111992.5A patent/HK1252685A1/zh unknown
- 2018-12-10 US US16/215,194 patent/US10526330B2/en active Active
-
2019
- 2019-11-20 US US16/689,706 patent/US10913740B2/en active Active
-
2021
- 2021-01-05 US US17/248,015 patent/US11299492B2/en active Active
-
2022
- 2022-03-07 US US17/688,001 patent/US11718616B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
EA201791576A1 (ru) | Ингибитор jak | |
CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
BR112017008103A2 (pt) | composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo. | |
BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
BR112017006264A2 (pt) | derivados de nucleosídeo substituído com 4?-vinila como inibidores de replicação de rna do vírus sincitial respiratório | |
CR20170426A (es) | Inhibidores de bace 1 | |
BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
EA202192822A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
BR112016018544A8 (pt) | Compostos ciclopropilaminas, composição farmacêutica que os compreende, seus usos no tratamento de câncer ou uma doença viral ou um beta-globinopatia e método de inibição de lsd1 | |
EA202091668A2 (ru) | Ингибиторы калликреина плазмы человека |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2016, OBSERVADAS AS CONDICOES LEGAIS |